Tocilizumab May Be Considered For Treating Patients With Moderate-To-Severe COVID-19-Associated Pneumonia And High C-Reactive Protein Levels, Study Suggests

Healio (5/24, Miller) reports researchers conducted “a follow-up analysis of the CORIMUNO-TOCI-1 randomized clinical trial” and found that “tocilizumab may be considered for treating patients with moderate-to-severe COVID-19-associated pneumonia and high...